(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of 452.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.39%.
Immutep's revenue in 2024 is $4,397,252.On average, 1 Wall Street analysts forecast IMMP's revenue for 2024 to be $4,624,566,435, with the lowest IMMP revenue forecast at $4,624,566,435, and the highest IMMP revenue forecast at $4,624,566,435. On average, 1 Wall Street analysts forecast IMMP's revenue for 2025 to be $4,624,566,435, with the lowest IMMP revenue forecast at $4,624,566,435, and the highest IMMP revenue forecast at $4,624,566,435.
In 2026, IMMP is forecast to generate $469,435,102,312 in revenue, with the lowest revenue forecast at $469,435,102,312 and the highest revenue forecast at $469,435,102,312.